Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck products Addressing Top 20 Global Burdens of Disease (%) (%)
Merck Impact Report
Latest, FY2025
100.0%
Period ended Dec 31, 2025
Change on a year earlier
+16.0 pts
84.0% in FY2024
History
5 years
Since FY2021
Sources
1
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Products Addressing Top 20 Global Burdens of Disease (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100.0% | +16.0 pts | – |
| FY2024 | Dec 31, 2024 | 84.0% | +1.0 pts | – |
| FY2023 | Dec 31, 2023 | 83.0% | 0.0 pts | – |
| FY2022 | Dec 31, 2022 | 83.0% | +12.0 pts | – |
| FY2021 | Dec 31, 2021 | 71.0% | – | – |
Cite this data
StockData. (2026). Merck Products Addressing Top 20 Global Burdens of Disease (%) (%), annual FY2021–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/esg_top20_disease_pct
See every metric in the Merck KPI table. Data updated Oct 26, 2026.